Back to Search Start Over

Interconnected influence: Unraveling purdue pharmaceutical's role in the global response to the opioid crisis.

Authors :
Bowra A
Perez-Brumer A
Forman L
Kohler JC
Source :
The International journal on drug policy [Int J Drug Policy] 2024 Nov; Vol. 133, pp. 104604. Date of Electronic Publication: 2024 Oct 19.
Publication Year :
2024

Abstract

Background: The global pharmaceutical industry has a long history of prioritizing profits over public health through widespread practices such as price gouging, deceptive marketing, and fraud. A prominent example of this issue is the mislabeling and mass-marketing of OxyContin by Purdue Pharmaceuticals (Purdue) that catalyzed the opioid crises in and beyond the United States.<br />Methods: Guided by Actor-Network Theory, this case study employs Visual Network Analysis to map the actors-networks involved in responding to the harms caused by Purdue. Data was generated from peer-reviewed and grey literature published between 2007 and 2022 (n = 40) and imported into Gephi visualization software where centrality metrics were applied.<br />Results: A total of 39 actors and 99 relationships were visualized based on the relational thinking that actors who are heavily interconnected with others are rendered important. Centrality measures identified the socio-technical centrality of Purdue in influencing the response to the harms it caused. Purdue exerted influence through various avenues, most prominently through the creation and cooptation of pain advocacy groups, their close ties with United States elected officials, and through embedding pro-opioid messaging in international guidance documents. In doing so, Purdue was able to extend the reach and impact of their opioid promotion, while simultaneously limiting the capacity of regulatory bodies to pursue accountability and implement policies to mitigate opioid-related harms.<br />Conclusion: This study advances understandings of the complex interplay between transnational pharmaceutical companies, global health systems, regulatory bodies, and public health. In doing so, we underscore the need for stronger regulation and increased transparency surrounding the interactions between pharma, patient groups, governments, and international organizations to better address and prevent future harms.<br />Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests Andrea Bowra reports financial support was provided by Government of Canada Social Sciences and Humanities Research Council. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-4758
Volume :
133
Database :
MEDLINE
Journal :
The International journal on drug policy
Publication Type :
Academic Journal
Accession number :
39427372
Full Text :
https://doi.org/10.1016/j.drugpo.2024.104604